Following medical training, Sarah undertook subsequent specialist training in Medical Oncology at Addenbrooke’s Hospital in Cambridge and the Royal Marsden Hospital, London. Sarah was awarded a CRUK Junior Clinician Scientist PhD fellowship to study fruit fly genetics at Cambridge University (2000-2004) and later held a Clinical Fellowship at the Institute of Cancer Research’s Drug Development Unit.

She was appointed as Senior Lecturer and Honorary Consultant at Imperial College in 2006 and established her laboratory studying the dysregulation of mRNA translation in cancer. In 2015 she moved to Oxford University as an Associate Professor of Experimental Oncology and was director of the Early Phase Clinical Trials Unit until 2021. She is Oxford's ECMC lead and runs a research group in the Old Road Campus Research Building. In July 2021, Sarah took over leadership of the Oxford Clinical Trials Office (OCTO). She has been chief or principal investigator for a number of national and international clinical studies, is involved in cancer prevention and early diagnosis and her research focus is post-transcriptional gene regulation in ovarian cancer.

Anna Fry is a Patient and Public Involvement (PPI) representative on a group exploring cancer prevention strategies for people at high risk. Anna has Lynch Syndrome – a genetic predisposition to developing certain cancers. It’s estimated 1 in 400 people have Lynch Syndrome (around 175,000 people in England) but only 5% of those people (“Lynchies”) are aware. Anna works in the field of cancer research but is here as a patient representative.

As the Senior Director for Strategic Operations, Catherine oversees Moderna’s significant investment into R&D activities and the expansion of our clinical trial footprint across the UK, Canada and Australia.

Catherine joined Moderna in October 2022 from the NHS, where she has spent over 12 years in a range of strategy, policy and transformation roles – national and local. Most recently she was Director of Technology Policy for NHS England and the Department of Health & Social Care, including developing plans to harness NHS data for research and innovation.

Dr Kirsty Wydenbach has been the Head of Regulatory Strategy at Weatherden, a global integrated consultancy, since 2022. Previously she has over 13 years’ experience as an Expert Medical Assessor at MHRA within the Clinical Trials Unit. Kirsty was involved in the UK regulation of clinical trials across all therapy areas and all phases of development, including ATMPs and many first-in-human studies. She also currently chairs the Clinical Trial Science and Regulations Expert Group of the Faculty of Pharmaceutical Medicine and is a visiting lecturer for King’s College London.

Since May 2021, Glen has been the Chief Medical Officer of TheraCryf plc, formerly Evgen Pharma plc., a clinical stage therapeutics company developing a new generation of innovative therapeutics in the oncology and behavioural brain disorder therapy areas. TheraCryf’s strategy is to generate compelling data sets with a goal of partnering its programmes with mid-size to large pharma.